BLFS (BioLife Solutions) Inventories, Finished Goods: $14.92 Mil (As of Mar. 2026)


BLFS BioLife Solutions Inc BLFS
72 GF Score
Price $28.64
GF Value $28.57
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Inventories, Finished Goods?

BioLife Solutions BLFS +4.25% 72 Inventories, Finished Goods is $14.92 Mil as of Mar. 2026. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.57 (Fairly Valued). The stock has 5 warning signs investors should review.

BioLife Solutions's quarterly finished goods declined from Sep. 2025 ($14.68 Mil) to Dec. 2025 ($13.22 Mil) but then increased from Dec. 2025 ($13.22 Mil) to Mar. 2026 ($14.92 Mil).

BioLife Solutions's annual finished goods increased from Dec. 2023 ($9.02 Mil) to Dec. 2024 ($13.16 Mil) and increased from Dec. 2024 ($13.16 Mil) to Dec. 2025 ($13.22 Mil).

BioLife Solutions Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for BioLife Solutions's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Inventories, Finished Goods Chart

BioLife Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.08 8.27 9.02 13.16 13.22

BioLife Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.23 14.27 14.68 13.22 14.92
BLFS
72GF Score
BioLife Solutions Inc BLFS
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLife Solutions Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $14.92 Mil mean?
BioLife Solutions (BLFS) has a Inventories, Finished Goods of $14.92 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on BioLife Solutions and its competitors.
Is BioLife Solutions' Inventories, Finished Goods too high?
BioLife Solutions' current Inventories, Finished Goods is $14.92 Mil. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Inventories, Finished Goods compare to KMTS and AZTA?
BioLife Solutions' Inventories, Finished Goods of $14.92 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Medical Devices & Instruments company?
A good Inventories, Finished Goods depends on the Medical Devices & Instruments industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on BioLife Solutions and its competitors. BioLife Solutions's current Inventories, Finished Goods is $14.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current Inventories, Finished Goods is $14.92 Mil. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Inventories, Finished Goods is $14.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for BLFS:

  • Inventories, Finished Goods: $14.92 Mil
  • GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score

Get the complete analysis for BLFS

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.64
Price
$28.57
GF Value